B
Bull
Bull · 25%NNNN
$51.40
Szenariopreis
$7.220
-0.079 (-1.10%)Zum Schluss
Loading chart…
- High
- 7.300
- Open
- 7.000
- VWAP
- 7.09
- Vol
- 273.86K
- Mkt Cap
- —
- Low
- 6.760
- Amount
- 1.94M
- EV/EBITDA, TTM
- 0.00
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
AI analysis of Anbio Biotechnology (NNNN)
buyAnbio Biotechnology (NNNN) appears to be a good buy right now due to its strong gross margin of 92.32% projected for Q2 2025 and a significant recent price increase of 12.63% over the last 5 days. The current price is $7.67, which is well below the Fibonacci resistance levels, indicating potential upside. However, the stock has seen a year-to-date decline of 73.98%, which is a considerable risk.
Bewertungskennzahlen
The current forward P/E ratio for Anbio Biotechnology (NNNN) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for NNNN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.507-09Yahoo FinanceAnbio Biotechnology Files Shelf Registration Statement
4.501-16Barron'sS&P 500 Futures Rise in Pre-Market Trading; QXO and Mosaic Underperform
2.012-04BenzingaUiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
5.008-09NewsfilterAnbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
5.008-09Yahoo FinanceAnbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
NNNN FAQ — answered by Alphio AI
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). It operates in the Healthcare sector.
Anbio Biotechnology (NNNN) appears to be a good buy right now due to its strong gross margin of 92.32% projected for Q2 2025 and a significant recent price increase of 12.63% over the last 5 days. The current price is $7.67, which is well below the Fibonacci resistance levels, indicating potential upside. However, the stock has seen a year-to-date decline of 73.98%, which is a considerable risk.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.